510(k) Report

510(k) · Cleared

Cleared

Topographic Imaging Marker

K990242510(k) TraditionalCleared Mar 3, 199937-day reviewClass II21 CFR 892.1680

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

I.Z.I. Medical Products Corp. · KPR System, X-Ray, Stationary

Cleared on Mar 3, 1999 after a 37-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Mar 3, 1999
Review
37 days
Class
Class II
Product code
KPR
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K990242Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KPR? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new KPR device

  1. #1 K242119 Innovision-Exiiscore 17.0 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All KPR devices

KPR System, X-Ray, Stationary: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · KPR

8in 2025

2007: 122008: 152009: 92010: 92011: 92012: 112013: 52014: 102015: 182016: 112017: 62018: 152019: 122020: 162021: 62022: 82023: 92024: 112025: 82026 (partial year): 6
2007high 18 (2015) · low 5 (2013)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KPR

155in 2025

2007: 31 days median2008: 48 days median2009: 35 days median2010: 126 days median2011: 152 days median2012: 58 days median2013: 163 days median2014: 108 days median2015: 81 days median2016: 84 days median2017: 75 days median2018: 30 days median2019: 33 days median2020: 39 days median2021: 55 days median2022: 43 days median2023: 76 days median2024: 162 days median2025: 155 days median2026 (partial year): 197 days median
2007high 197 (2026) · low 30 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · KPR

7in 2025

2007: 102008: 102009: 52010: 32011: 52012: 12013: 52014: 82015: 12016: 42017: 32018: 42019: 12020: 12022: 22023: 42024: 12025: 7
2007high 10 (2007) · low 0 (2021)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KPR

39in 2025

2007: 1202008: 952009: 612010: 822011: 1032012: 742013: 242014: 342015: 592016: 182017: 312018: 362019: 772020: 412021: 372022: 272023: 392024: 342025: 39
2007high 120 (2007) · low 18 (2016)2025

MAUDE reports naming product code KPR, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007123110120
200815481095
2009935561
20109126382
201191525103
20121158174
20135163524
201410108834
20151881159
20161184418
2017675331
20181530436
20191233177
20201639141
2021655037
2022843227
2023976439
202411162134
20258155739
202661970—

What is it indicated for?

The 1ZI Topographic Imaging Marker provides a Jocation on the patient’s skin to reference internal anatomy and pathology. Given any radiographic information thereby, a physician or technician can pinpoint the location of the patient’s ailment on the skin surface in reference to an internal pathologic process. The subsequent radiographic study would enable one to cross reference the skin position indicated by thc patient with the internally demonstrated…

Read the full statement (103 words)

The 1ZI Topographic Imaging Marker provides a Jocation on the patient’s skin to reference

internal anatomy and pathology. Given any radiographic information thereby, a physician or

technician can pinpoint the location of the patient’s ailment on the skin surface in reference to an

internal pathologic process. The subsequent radiographic study would enable one to cross

reference the skin position indicated by thc patient with the internally demonstrated pathologic

process shown on the study.

The 1Z] Topographic Imaging Marker is used for all fluoroscopic procedures, all standard

radjographic procedures, localization of internal anatomy and pathology, as well as being able to

direct biopsy procedures.

Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K990242: Topographic Imaging Marker.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K990242

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026